Characteristic | Frequency | % | ||
---|---|---|---|---|
 | Median (years) | 54 (range, 22-78) | ||
Age | <60 | 63 | 61.2 | |
 | ≥ 60 | 40 | 38.8 | |
Sex | Male | 58 | 56.3 | |
 | Female | 45 | 43.7 | |
 | Absent | 92 | 89.3 | |
Carcinoid symptom | Present | 5 | 4.9 | |
 | Unavailable | 6 | 5.8 | |
 | Pancreas | 26 | 25.2 | |
 | GI tract | 27 | 26.2 | |
 |    Foregut | 11 | 10.7 | |
 |    Midgut | 1 | 1.0 | |
Origin |    Hindgut | 15 | 14.6 | |
 | Lung | 2 | 1.9 | |
 | Etc.* | 28 | 27.2 | |
 | Unknown | 20 | 19.4 | |
Initial metastatic site | Liver | 50 | 74.6 | |
 | Bone | 12 | 17.9 | |
 | Lung | 12 | 17.9 | |
 | Brain | 3 | 4.5 | |
 | Lymph node | 20 | 29.9 | |
 | Etc. | 10 | 14.9 | |
Recurrent site | Liver | 15 | 41.7 | |
 | Bone | 16 | 44.4 | |
 | Lung | 1 | 2.8 | |
 | Brain | 1 | 2.8 | |
 | Lymph node | 15 | 41.7 | |
 | Etc. | 3 | 8.3 | |
 | Local | 21 | 21.4 | |
Prior stage | Regional | 15 | 14.6 | |
 | Distant | 67 | 65.0 | |
 | 1 | 34 | 33.0 | |
 | 2 | 1 | 1.0 | |
Grade | 3 | 15 | 14.6 | |
 | Large | 9 | 8.7 | |
 | Small | 7 | 6.8 | |
 | Unclassified | 25 | 24.3 | |
 | Unavailable | 12 | 11.7 | |
 |  | Median (range) | 23.0 (2.6-1324.6) | |
 | 24-hour urine 5-HIAA (μmol/day)†| <31.4 (reference range) | 15 | 71.4 |
Biomarkers |  | ≥ 31.4 | 6 | 28.6 |
 |  | Median (range) | 1.6 (0.4-23.1) | |
 | Serum NSE (nmol/l)‡ | <1.0 (reference range) | 12 | 36.4 |
 |  | ≥ 1.0 | 21 | 63.6 |